Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

por Schwedt, Todd J., Kuruppu, Dulanji K., Dong, Yan, Standley, Katherine, Yunes-Medina, Laura, Pearlman, Eric
Publicado 2021

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments

por Kuruppu, Dulanji K., Tobin, Joshua, Dong, Yan, Aurora, Sheena K., Yunes-Medina, Laura, Green, A. Laine
Publicado 2021

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials

por Kuruppu, Dulanji K., North, James M., Kovacik, Amy J., Dong, Yan, Pearlman, Eric M., Hutchinson, Susan L.
Publicado 2021

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

por Ailani, Jessica, Kuruppu, Dulanji K., Rettiganti, Mallikarjuna, Oakes, Tina, Schroeder, Krista, Wietecha, Linda, Port, Martha, Blumenfeld, Andrew M.
Publicado 2022

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

por Andrews, J Scott, Kudrow, David, Rettiganti, Mallikarjuna, Oakes, Tina, Bardos, Jennifer N, Wenzel, Richard, Kuruppu, Dulanji K, Gaul, Charly, Martinez, James M
Publicado 2021

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

por Láinez, Miguel J. A., Schoenen, Jean, Stroud, Chad, Bardos, Jennifer, Bangs, Mark, Kemmer, Phebe, Wenzel, Richard, Kuruppu, Dulanji K., Martinez, James Michael, Oakes, Tina M.
Publicado 2021